Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright

Urogen Pharma (NASDAQ:URGN) – Investment analysts at HC Wainwright upped their Q3 2027 earnings estimates for Urogen Pharma in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.36 per share for the quarter, up from their previous forecast of $0.28. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2027 earnings at $0.50 EPS.

Other research analysts have also issued research reports about the company. TD Cowen lifted their price target on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. Guggenheim raised their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday. Oppenheimer lifted their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Finally, UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.78.

Urogen Pharma Stock Down 1.8%

Shares of NASDAQ URGN opened at $45.60 on Friday. The business has a 50-day moving average price of $36.07 and a 200 day moving average price of $26.98. The stock has a market cap of $2.22 billion, a PE ratio of -23.03 and a beta of 1.57. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $48.03.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the insider owned 119,763 shares in the company, valued at approximately $4,790,520. This represents a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,222 shares of company stock worth $892,661 in the last three months. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Urogen Pharma

A number of large investors have recently made changes to their positions in the stock. Paradigm Biocapital Advisors LP purchased a new stake in shares of Urogen Pharma in the third quarter valued at about $84,111,000. Soleus Capital Management L.P. purchased a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $29,934,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Urogen Pharma during the 4th quarter worth approximately $26,350,000. MPM Bioimpact LLC raised its position in shares of Urogen Pharma by 597.3% during the 4th quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock worth $22,047,000 after purchasing an additional 806,378 shares during the last quarter. Finally, TCG Crossover Management LLC purchased a new stake in Urogen Pharma in the 3rd quarter valued at approximately $14,311,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma News Summary

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $75 from $45 and reiterated a Buy rating. The new target implies approximately 64.5% upside from the referenced $45.60 price, signaling increased analyst confidence in Urogen’s commercial outlook. Benzinga The Fly
• Positive Sentiment: Second-quarter revenue was $72.46 million, above the $63.55 million analyst estimate. The company reported $50.4 million in ZUSDURI revenue, providing evidence of meaningful commercial traction and supporting the bullish analyst view. Urogen second-quarter financial results
• Neutral Sentiment: Management discussed the second-quarter results and company outlook during its earnings call, which investors may use to assess ZUSDURI’s sales trajectory, operating plans, and path toward profitability. Urogen Q2 2026 earnings call transcript
• Negative Sentiment: Urogen reported a quarterly loss of $0.28 per share, slightly worse than the $0.26 consensus estimate. Although the loss improved substantially from $1.05 per share a year earlier, continued losses and the EPS miss may be prompting profit-taking after the stock’s sharp run-up. Urogen earnings report

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.